Sanofi has teamed up with Ping An to create the first integrated management project for ACS confirmed patients.

Introduction: Sanofi has signed a cooperation agreement with Ping An of China, and the two sides will jointly carry out the Sanofi Ping An Lida project based on the risk management of high-risk patients with acute coronary syndrome (ACS).
On August 11, 2020, Sanofi signed a cooperation agreement with Ping An of China to jointly launch Sanofi Ping Lida project based on risk management of high-risk patients with acute coronary syndrome (ACS), to provide health guidance to high-risk patients with acute coronary syndrome, popularize the concept of lipid management and cardiovascular event prevention and protection, and work together to provide better health financial services for Chinese patients.
is the first AI technology to help high-risk patients with acute coronary syndrome assess risk and risk management, and the first insurance program to cover postoperative risk in patients with high risk of acute coronary syndrome.
, deputy general manager of Ping An Insurance Co., Ltd., said, "This Ping An and Sanofi cooperation is the first to design cardiovascular risk protection insurance for patients with confirmed acute coronary syndrome.
combined with the strengths of both sides will not only help to solve the huge medical needs that are not met in the Chinese market, but will also improve people's awareness of health and access to medical services, improve the quality of medical services and improve the medical burden of patients.
" acute coronary syndrome (ACS) has become one of the main causes of death in China, the incidence rate in recent years is still on the rise.
Hospital and out-of-hospital recurrence risk cognition is insufficient, patients pay low attention to the disease management is not in place, drug compliance is poor and a series of reasons, so that the risk of recurrence of patients increased, the burden of disease further increased.
AFTER ACS patients, even if they have received evidence-based preventive treatment, there is still a high risk of residues associated in part with low-density lipoprotein cholesterol (LDL-C) levels, so reducing LDL-C is at the heart of secondary prevention in ACS patients.
The innovative drug Alisiyu monoantigen injections, which have just landed in China in April 2020, not only have evidence-based evidence to significantly reduce cardiovascular events in ACS patients, but are also the only PCSK9 inhibitors proven to be associated with a 15% decrease in all-cause deaths, significantly reducing LDL-C levels by 61% for recent ACS patients who have been treated with statins.
Based on the risk management of high-risk patients with acute coronary syndrome, Sanofi and Ping An Group will launch the Ping An Lida project, which combines Sanofi's products in acS risk management-related fields, through the management platform for coronary heart disease patients provided by Ping An Group's Ping An International Smart City Technology Co., Ltd. and the innovative post-coronary risk commercial insurance products designed and developed by Ping An Property Insurance Co., Ltd., which combine clinical management, pharmaceutical services and commercial insurance to provide patients with intimate disease management services.
As a leader in the field of chronic disease prevention and treatment, Sanofi China Cardiovascular and Mature Products Division General Manager Liu Wei said: "This partnership is the first to integrate insurance product design and development, chronic patient management, medical AI technology applications, drug benefit management patient payment and insurance after Sanofi established a strategic partnership with Ping An Group. And follow-up integration and other forms of cooperation projects, we will be in line with the 'patient-centered' purpose, make full use of Sanofi's in-depth understanding of the medical industry and disease management, combined with Ping An in the financial and technical advantages, to achieve leapfrog cooperation for the vast number of patients with acute coronary syndrome and their families to provide scientific, professional medical and health services.
believes that as the cooperation deepens, the goal of 'improving health awareness and access to medical services' in the direction of strategic cooperation will be fulfilled, Sanofi will continue to bring innovative medical solutions to Chinese people.
" collaboration will not only help to raise awareness of risk management in high-risk patients with acute coronary syndrome and reduce the postoperative risk of coronary heart disease who undergo coronary surgery, but will also improve the quality of medical services and the affordability of medical services.
based on the data and model precipitated by the intelligent medical platform, the two sides explore innovative models for cooperation in commercial insurance, medical insurance, etc., build multi-level medical security systems, improve disease management efficiency, and control overall medical costs.
also explore new ways to provide more intelligent and efficient care services, improve patient compliance and accessibility, and make disease management more efficient, convenient and intelligent.
Sanofi and Ping An Group, in addition to fulfilling the cooperation agreement on existing projects, also intend to further deepen cooperation, expand the scope of cooperation, cooperation to expand the direction of more diseases and treatment areas, and may be involved in the entire life cycle of patient disease management.
.